echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Arthritis Rheumatol: Type I interferon plays a key role in the development of cardiovascular disease in patients with systemic lupus erythematosus

    Arthritis Rheumatol: Type I interferon plays a key role in the development of cardiovascular disease in patients with systemic lupus erythematosus

    • Last Update: 2021-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Neutrophil disorders and type I interferon (IFN) can cause congenital axis medsci.


    medsci.


    The study included patients with moderate to severe systemic lupus erythematosus who participated in phase IIb of the MUSE trial, and healthy people served as the control group.


    Immune cholesterol

     

    The analysis results showed that the formation of NET complex, tumor necrosis factor (TNF) and interleukin-10 (IL-10) levels are related to the activity of type I IFN pathway.


    In summary, the results of this study support the key role of type I IFNs in regulating the vascular pathology that leads to systemic lupus erythematosus, and show that inhibiting this pathway can reduce the cardiovascular risk of patients with systemic lupus erythematosus.


     

    Original source:

     

    Kerry A Casey, et al.


    ncbi.
    nlm.
    nih.
    gov/32909675/" target="_blank" rel="noopener">Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.